Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Pharma stock Theralase Technologies (TSXV:TLT) announced a significant update on its ongoing bladder cancer clinical study ...

Research from Purdue University in collaboration with the National Institutes of Health (NIH) reveals that a cancer drug ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 ...

A groundbreaking protocol promises significant advances for patients with bladder cancer. New therapeutic combinations show ...